---
document_datetime: 2026-01-29 15:39:52
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/spinraza-epar-all-authorised-presentations_en.pdf
document_name: spinraza-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8389108
conversion_datetime: 2026-02-01 20:21:58.318477
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.1
  docling: 2.71.0
  docling-core: 2.62.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number    | (Invente d) name   | Streng th   | Pharmaceuti cal Form   | Route of Administrati on   | Immedia te Packagin g   | Content (concentrati on)   | Pac k siz e   |
|-------------------|--------------------|-------------|------------------------|----------------------------|-------------------------|----------------------------|---------------|
| EU/1/17/1188/ 001 | Spinraza           | 12 mg       | Solution for injection | Intrathecal use            | vial (glass)            | 5 ml (2.4 mg/ml)           | 1 vial        |
| EU/1/17/1188/ 002 | Spinraza           | 28 mg       | Solution for injection | Intrathecal use            | vial (glass)            | 5 ml (5.6 mg/ml)           | 1 vial        |
| EU/1/17/1188/ 003 | Spinraza           | 50 mg       | Solution for injection | Intrathecal use            | vial (glass)            | 5 ml (10 mg/ml)            | 1 vial        |